Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262546 | 0.93 | MAPK1 (0.48) | MAPK1TP53RAB9ANCOA1NCOA3 | |
| SCHEMBL2093992 | 0.85 | SLC6A9 (0.44) | RAB9AALDH1A1L3MBTL1BACE1 | |
| SCHEMBL3759367 | 0.77 | PTGDR2 (0.57) | MAPK1TP53RAB9AALDH1A1HSD17B10 | |
| SCHEMBL1680715 | 0.76 | ALDH1A1 (0.52) | TP53RAB9AALDH1A1HSD17B10HTR7 | |
| SCHEMBL5718989 | 0.76 | MAPK1 (0.52) | MAPK1TP53RAB9AALDH1A1HTR7 | |
| SCHEMBL2059488 | 0.73 | NCOA1 (0.59) | MAPK1TP53RAB9ANCOA1NCOA3 | |
| SCHEMBL112422 | 0.72 | NCOA1 (0.63) | MAPK1TP53RAB9ANCOA1NCOA3 | |
| SCHEMBL1533468 | 0.71 | DRD1 (0.42) | MAPK1TP53RAB9ANCOA1NCOA3 | |
| SCHEMBL5355819 | 0.71 | TDP1 (0.40) | MAPK1TP53RAB9ANCOA1NCOA3 | |
| SCHEMBL5718987 | 0.71 | HTR7 (0.41) | MAPK1TP53RAB9ANCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7829585-B2 | Antifungal agent containing pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1864980-A1 | ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | MAPK1 683/4885TP53 4846/4885RAB9A 1945/4885 |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | MAPK1 1626/4885TP53 2758/4885RAB9A 1844/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | MAPK1 1691/4885TP53 2795/4885RAB9A 1739/4885 |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | ERG28, SQOR, CYP51A1 | MAPK1 809/4885TP53 3139/4885RAB9A 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.